



ASX ANNOUNCEMENT

24 July 2017

## NDF's Stuart Roberts Initiates Cynata Research Coverage

**Melbourne, Australia; 24 July 2017:** Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that widely respected life sciences industry analyst Stuart Roberts of NDF Research has initiated equity analyst coverage with the release of a new report on Cynata.

NDF provides expert independent equity research of innovative biotech companies focusing on life sciences companies that are publicly traded on the Australian Securities Exchange (ASX).

The full NDF Research report can be viewed on Cynata's website at [www.cynata.com](http://www.cynata.com).

**Ends**

**CONTACTS:** Dr Ross Macdonald, CEO, 0412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Andrew Ramadge, Australia Media Contact, 0475 797 471, [andrew.ramadge@mcpartners.com.au](mailto:andrew.ramadge@mcpartners.com.au)  
Laura Bagby, U.S. Media Contact, 312-448-8098, [lbagby@6degreespr.com](mailto:lbagby@6degreespr.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus' novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata's unique "off-the-shelf" Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.